SCHEMBL6711250

SCHEMBL6711250

Cc1ccc(C(=S)OC(C(=O)c2ccncc2)c2ccc(F)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LTA4H P09960 1/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.42
▸ CYP3A4 P08684 4/20 0.41
▸ CYP2C19 P33261 3/20 0.41
▸ CYP1A2 P05177 3/20 0.41
▸ CYP2C9 P11712 2/20 0.41
▸ ALDH1A1 P00352 3/20 0.40
▸ LMNA P02545 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ GAA P10253 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ CA1 P00915 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ POLB P06746 1/20 0.36
▸ CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6707553 0.96 NPSR1 (0.43) LTA4HNPSR1CYP3A4CYP2C19CYP1A2
SCHEMBL7229213 0.76 MAPT (0.63) LTA4HNPSR1CYP2C19CYP1A2CYP2C9
SCHEMBL6709697 0.74 KMT2A (0.54) LTA4HNPSR1CYP3A4ALDH1A1LMNA
SCHEMBL6711247 0.72 LTA4H (0.45) LTA4HCYP1A2ALDH1A1LMNASMN1; SMN2
SCHEMBL6707552 0.72 KMT2A (0.58) LTA4HNPSR1CYP3A4ALDH1A1LMNA
SCHEMBL7229777 0.72 MAPT (0.64) LTA4HNPSR1CYP2C19CYP1A2CYP2C9
SCHEMBL7355965 0.71 LTA4H (0.43) LTA4HALDH1A1SMN1; SMN2L3MBTL1KMT2A
SCHEMBL27907449 0.71 L3MBTL1 (0.53) LTA4HALDH1A1CA1CA9L3MBTL1
SCHEMBL6319785 0.69 CES2 (0.43) CYP3A4ALDH1A1LMNASMN1; SMN2TDP1
SCHEMBL6752455 0.68 LTA4H (0.43) LTA4HCYP1A2ALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0727998-B1 OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORP (US) 2004-01-21 — — EP disclosed
EP-1306377-A2 Pyridyl-oxazoles and their use as cytokines inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2003-05-02 — — EP disclosed
US-20020169173-A1 Oxazoles for treating cytokine mediated diseases SMITHKLINE BEECHAM CORPORATION 2002-11-14 — — US disclosed
US-6288062-B1 INTERLEUKIN AND TUMOR NECROSIS FACTOR INHIBITORS; ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; RESPIRATORY SYSTEM DISORDERS SMITHKLINE BEECHAM CORPORATION 2001-09-11 — — US disclosed
EP-0727998-A4 OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORP (US) 1997-03-19 — — EP disclosed
EP-0727998-A1 OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION (US) 1996-08-28 — — EP disclosed
WO-1995013067-A1 OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION (US) 1995-05-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169173-A1 Oxazoles for treating cytokine mediated diseases IL17A, IL4I1, IL2 LTA4H 119/4885NPSR1 1782/4885CYP3A4 1436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback